aristolochic acid i has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HR; Chang, YC; Lian, JD; Lo, CW; Wang, CJ; Yang, MY | 1 |
| Hattori, T; Jankovic Velickovic, L; Stefanovic, V | 1 |
2 other study(ies) available for aristolochic acid i and cyclin d1
| Article | Year |
|---|---|
Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2.
Topics: Administration, Oral; Animals; Aristolochic Acids; Carcinogens; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; Immunoprecipitation; Male; Rats; Rats, Wistar; Urinary Bladder; Urothelium | 2006 |
Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease.
Topics: Adult; Aged; Aged, 80 and over; Aristolochia; Aristolochic Acids; Balkan Nephropathy; Biomarkers, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Kidney Pelvis; Male; Middle Aged; Neoplasm Proteins; Receptor, ErbB-2; Risk Factors; Tumor Suppressor Protein p53; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms; Young Adult | 2009 |